News releases
June 07, 2024
Boehringer Ingelheim’s survodutide shows significant improvement in liver fibrosis with no worsening of MASH in 64.5% of patients with F2 and F3 fibrosis
May 07, 2024
Boehringer Ingelheim receives Health Canada approval for SENVELGO™, the once-daily liquid oral solution for newly diagnosed diabetes in cats
April 16, 2024
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
Media contacts
Communications, Media & Public Relations
Director, Communications
Phone (905) 631-4713
Mobile (905) 599-2364
Communications, Media & Public Relations
Corporate Communications
Phone (905) 631-4531
Mobile (647) 637-8265
